↓ Skip to main content

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers

Overview of attention for article published in Breast Cancer Research, February 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#46 of 1,855)
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
5 news outlets
blogs
1 blog
twitter
10 tweeters
patent
4 patents

Citations

dimensions_citation
205 Dimensions

Readers on

mendeley
287 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Published in
Breast Cancer Research, February 2016
DOI 10.1186/s13058-015-0661-5
Pubmed ID
Authors

Richard S. Finn, Alexey Aleshin, Dennis J. Slamon

Abstract

Despite significant advances in early detection and treatment, breast cancer still remains a major cause of morbidity and mortality for women. Our understanding of the molecular heterogeneity of the disease has significantly expanded over the past decade and the role of cell cycle signaling in both breast cancer oncogenesis and anti-estrogen resistance has gained increasing attention. The mammalian cell cycle is driven by a complex interplay between cyclins and their associated cyclin-dependent kinase (CDK) partners, and dysregulation of this process is one of the hallmarks of cancer. Despite this, initial results with broadly acting CDK inhibitors were largely disappointing. However, recent preclinical and phase I/II clinical studies using a novel, oral, reversible CDK4/6 inhibitor, palbociclib (PD-0332991), have validated the role of CDK4/6 as a potential target in estrogen receptor-positive (ER+) breast cancers. This review highlights our current understanding of CDK signaling in both normal and malignant breast tissues, with special attention placed on recent clinical advances in inhibition of CDK4/6 in ER+ disease.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 287 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 <1%
Netherlands 1 <1%
Unknown 285 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 48 17%
Student > Bachelor 46 16%
Student > Ph. D. Student 42 15%
Researcher 34 12%
Other 20 7%
Other 37 13%
Unknown 60 21%
Readers by discipline Count As %
Medicine and Dentistry 63 22%
Biochemistry, Genetics and Molecular Biology 59 21%
Agricultural and Biological Sciences 36 13%
Pharmacology, Toxicology and Pharmaceutical Science 17 6%
Chemistry 16 6%
Other 33 11%
Unknown 63 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 57. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 July 2022.
All research outputs
#583,367
of 21,745,818 outputs
Outputs from Breast Cancer Research
#46
of 1,855 outputs
Outputs of similar age
#12,297
of 378,373 outputs
Outputs of similar age from Breast Cancer Research
#1
of 13 outputs
Altmetric has tracked 21,745,818 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,855 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.8. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 378,373 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.